ClinicalTrials.gg

Vomiting clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 794 studies for Vomiting across more than 10 countries. 99 are recruiting or about to start. 248 of them are mainly about Vomiting (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16. Counting its 2 narrower conditions too, such as Postoperative Nausea and Vomiting: 1,368 studies, 206 open.

ClinicalTrials.gov finds 1,595 studies for Vomiting. How that becomes 793 here

This page counts the studies the registry files under Vomiting, and those it files under no condition that list Vomitingthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 1,595Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −572Filed under a narrower condition, counted on its own pagePostoperative Nausea and Vomiting 545 · Hyperemesis Gravidarum 25
  3. −43List Vomiting as a condition, but the registry did not file them under itMost often written as “Cyclic Vomiting Syndrome” (11), “Nausea and Vomiting Caused by Chemotherapy” (4), and “Vomiting Syndrome” (2). The registry filed them under other conditions only, most often Nausea (19) and Familial cyclic vomiting syndrome (15).
  4. −187Match it another way164 name it in the title, 8 in a keyword, and 15 by a synonym or other text the search reads.
  5. 793The count on this page24 of them list Vomiting in their own words; the registry filed them under no condition.

Status

Completed
489
Status unknown
109
Terminated
56
Recruiting
56
Not yet recruiting
35
Withdrawn
29

Phase

Phase 2
151
Phase 3
151
Phase 4
101
Phase 1
59
Early Phase 1
4

Where

United States
286
China
73
Turkey
62
Canada
44
Korea, Republic of
29
Italy
27

Who develops what

Add Vomiting to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 11 programs from 8 companies, 3 with this as their studies’ main aim; 1 with a live phase 3 study; 5 primary completions in the next 12 months. Compare Bristol-Myers Squibb, Qilu Pharmaceutical and Eli Lilly here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
OndansetronRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT07681076 · Bristol-Myers Squibb · Phase 4 · live · background · “Ondansetron” · registered Jun 2026
  • NCT06904235 · Helsinn Healthcare SA · Phase 2 · live · comparator · “Reference Treatment: IV ondansetron infusion” · registered Dec 2024
  • NCT02106494 · Heron Therapeutics · Phase 3 · comparator · “Ondansetron” · registered Mar 2014
  • NCT01732458 · Merck & Co., Inc · Phase 2 · comparator · “Ondansetron” · registered Nov 2012
  • NCT01636947 · Merck & Co., Inc · Phase 4 · background · “Ondansetron” · registered Jul 2012
Merck & Co., Inc14% of its industry studies22 studies

6 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 11 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (5)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 30 Nov 2026 est.xanomeline, trospium · Bristol-Myers Squibb · Phase 4 registry mapping onlystudied with Ondansetronstudied with trimethobenzamidestudied with MeclizineNCT07681076 Study to Assess Safety and Tolerability of KarXT With Administration of Antiemetics in Healthy Volunteers — primary endpoint: Number of participants with Treatment Emergent Adverse Events (TEAEs) · 180 enrolled
  • Dec 2026 est.GIPR Agonist LY3537021 · Eli Lilly and Company · Phase 2 named, not the main aimNCT07169851 A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer — primary endpoint: Proportion of Participants with a Complete Response (CR) in the Delayed Phase of CINV · 204 enrolled
  • Dec 2026 est.HRS5580 · Jiangsu HengRui Medicine Co., Ltd. · Phase 2 main aimNCT07709897 A Clinical Trial of HRS5580 for Injection Combined With Palonosetron Hydrochloride for the Prevention of Postoperative Nausea and Vomiting — primary endpoint: Complete response rate within 72 hours after extubation (defined as the proportion of participants with no vomiting and no use of rescue therapy) · 260 enrolled

2 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Vomiting studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Antiemetics 10 open · 5-HT3 antagonists 5 open · NK1 receptor antagonists 5 open · Antipsychotics 4 open · Antimuscarinics 1 open

Coming up

35studies finish main data collection within a year5 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 56 Vomiting studies recruiting now, 26 (46%) set no upper age limit and 24 (43%) stop at 75 or younger. 10 (18%) take children under 18. 5 (9%) are for women only and 0 (0%) for men only; 17 (30%) take healthy volunteers.

Recruiting studies that take each age, of 56
AgeWomenMen
107 (13%)7 (13%)
1848 (86%)43 (77%)
3049 (88%)44 (79%)
4049 (88%)44 (79%)
5047 (84%)44 (79%)
6547 (84%)44 (79%)
7540 (71%)37 (66%)
8530 (54%)27 (48%)

Across all 794 studies, recruiting or not: 46% stop at 75 or younger and 37% at 65; 20% take children; 18% are for women only and 2% for men only; 18% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Vomiting studies take

Of 56 phase 3 interventional studies under Vomiting, half reached primary completion within 21 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 14 mo3–14 · 19 studies——
Phase 222 mo13–31 · 41 studies——
Phase 321 mo12–38 · 56 studies—24 mo12–51 · 37 studies
Phase 417 mo8–32 · 41 studies—17 mo8–43 · 31 studies
Interventional, no phase13 mo6–31 · 135 studies—13 mo5–29 · 132 studies
Observational26 mo10–63 · 37 studies—33 mo10–63 · 35 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 794. Browse all 794 → or search them.